European Bank for induced pluripotent Stem Cells
The European Bank for induced pluripotent Stem Cells (EBiSC) is a non-profit induced pluripotent stem cell (iPSC) biorepository and service provider with central facilities in Germany and the United Kingdom.
EBiSC was set up between 2014 and 2017 by a consortium that represented researchers, clinicians and industry stakeholders.[1] A second phase of the project runs between 2019 and 2022 with the aim of consolidating EBiSC as a not-for-profit, self-sustainable iPSC bank and service provider.[2] The initiative is funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations under the Innovative Medicines Initiative.[3][4]
The European Bank for induced pluripotent Stem Cells performs collection, banking, quality control and distribution of iPSC lines for research purposes. EBiSC's stated goal is to supply academic, non-profit and commercial researchers with quality-controlled, disease-relevant iPSC lines, data and other services. It also seeks to promote the international standardisation of iPSC banking practices and to act as a central hub that ensures the sustainability and accessibility of iPSC lines generated by different research organisations. IPSC lines generated externally can be deposited into EBiSC for storage, banking, quality control and distribution.[5][6][7][8]
Catalogue and facilities[edit]
In February 2020, the EBiSC catalogue contained iPSC lines representing diseases and conditions such as Alzheimer's disease,[9] Frontotemporal Dementia, Parkinson's disease, Huntington's disease, Dravet syndrome, Bardet-Biedl syndrome, depression and pain, diabetes mellitus, eye diseases and heart disease.[10] These iPSC lines have been deposited into EBiSC by academic institutions and non-profit and commercial organisations internationally. This includes lines generated within research projects such as StemBANCC, HipSci, IMI-ADAPTED, CRACK IT BadIPS and CRACK IT UnTangle.
The EBiSC Bank is run by two central facilities: the main distributor of EBiSC cell lines, the European Collection of Authenticated Cell Cultures in the UK, and the 'mirror bank' storing duplicates of all deposited lines long-term, established by the Fraunhofer Institute for Biomedical Engineering (IBMT) in Germany.
All EBiSC lines are distributed by the European Collection of Authenticated Cell Cultures operated by Public Health England.
References[edit]
- ^ "European Bank for induce pluripotent Stem Cells". CORDIS: EU Research Results. EU Publications Office. Retrieved 20 July 2020.
- ^ "A sustainable European Bank for induced pluripotent Stem Cells". CORDIS: EU Research Results. EU Publications Office. Retrieved 20 July 2020.
- ^ "EBiSC". Innovative Medicines Initiative. European Commission, European Federation of Pharmaceutical Industries and Associations. Retrieved 20 July 2020.
- ^ "EBiSC2". Innovative Medicines Initiative. European Commission, European Federation of Pharmaceutical Industries and Associations. Retrieved 20 July 2020.
- ^ De Sousa, Paul A. (2017). "Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience". Stem Cell Research. 20 (April 2017): 105–114. doi:10.1016/j.scr.2017.03.002. hdl:20.500.11820/0a4f24c0-4c92-4b25-b507-ccaae4dae461. PMID 28334554.
- ^ Steeg, Rachel (2020). "Development and implementation of large-scale quality control for the European bank for induced Pluripotent Stem Cells". Stem Cell Research. 45 (May 2020): 101773. doi:10.1016/j.scr.2020.101773. PMID 32252012.
- ^ Engle, Sandra J. (21 November 2018). "Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons". Neuron. 100 (4): 783–797. doi:10.1016/j.neuron.2018.10.033. PMID 30465765. S2CID 53718512.
- ^ Scudellari, Megan (16 June 2016). "A decade of iPS cells" (PDF). Nature. 534 (7607): 310–312. doi:10.1038/534310a. PMID 27306170. Retrieved 20 July 2020.
- ^ "EBiSC to develop next generation Alzheimer's disease iPSC lines". Public Health England. Retrieved 20 July 2020.
- ^ "EBiSC: New panel of heart disease-specific iPSC lines for in vitro disease modelling and drug testing". Public Health England. Retrieved 20 July 2020.